The company uses a transformative approach to identify drug targets and develop antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Their antibodies are found through an unbiased and function-first approach using three complementary processes and technologies. Alchemab collaborates with patient representative groups and biobanks globally to further their understanding of disease and enable their engine. By harnessing the naturally protective power of patient antibodies, Alchemab aims to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.